Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2414

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Mantle cell lymphoma continues to surprise, and inform!

Michael E. Williams

Blood (2021) 137 (23): 3158–3160.

https://doi.org/10.1182/blood.2020010622

Published: 2021

Journal Articles

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Blood (2021) 137 (23): 3251–3258.

https://doi.org/10.1182/blood.2020008835

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Under the cover of mantle cell lymphoma

Birgitta Sander

Blood (2020) 136 (12): 1378–1379.

https://doi.org/10.1182/blood.2020006581

Published: 2020

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood (2020) 136 (5): 572–584.

https://doi.org/10.1182/blood.2019002385

Published: 2020

Includes: Supplemental data

Journal Articles

UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells

Samantha A. Swenson, Tyler J. Gilbreath, Heather Vahle, R. Willow Hynes-Smith, Jared H. Graham, Henry C.-H. Law, Catalina Amador, Nicholas T. Woods, Michael R. Green, Shannon M. Buckley

Blood (2020) 136 (3): 299–312.

https://doi.org/10.1182/blood.2019002102

Published: 2020

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Christian Winther Eskelund, Simon Husby, Francesco Favero, Tobias Wirenfeldt Klausen, Francisco German Rodriguez-Gonzalez, Arne Kolstad, Lone Bredo Pedersen, Riikka Katariina Räty, Christian H. Geisler, Mats Jerkeman, Joachim Weischenfeldt, Kirsten Grønbæk

Blood (2020) 135 (22): 2000–2004.

https://doi.org/10.1182/blood.2019003539

Published: 2020

Includes: Supplemental data

Journal Articles

Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen

Chieh Lin Fu, Maria Julia Diacovo

Blood (2020) 135 (10): 778.

https://doi.org/10.1182/blood.2019003479

Published: 2020

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Blood (2019) 134 (Supplement_1): 3988.

https://doi.org/10.1182/blood-2019-125800

Published: 2019

Journal Articles

Cellular and Molecular Characterization of Breast Cancer Chemotherapy-Related B Cell Lymphomas

Madeline Rodriguez Valentin, PhD, Darwing Rivas, BSc, Vesna Jurecic, BSc, Alain Diaz, PhD, Richard Riley, PhD, Daniela Frasca, PhD, Roland Jurecic, PhD

Blood (2019) 134 (Supplement_1): 5241.

https://doi.org/10.1182/blood-2019-127252

Published: 2019

Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 5243.

https://doi.org/10.1182/blood-2019-122759

Published: 2019

Journal Articles

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Aleksandra Golos, MD PhD, Krzysztof Mądry, MD PhD, Karol Lis, Marta Sobas, MD, Agnieszka Ożańska, Magdalena Czemerska, Dorota Hawrylecka, Agnieszka Stelmach-Gołdyś, Karolina Chromik, Bartosz Pula, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD

Blood (2019) 134 (Supplement_1): 5422.

https://doi.org/10.1182/blood-2019-125711

Published: 2019

Journal Articles

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Ghada Zakout, FRCPATH, MRCP (UK), MBBCh (Hon), Charalampia Kyriakou

Blood (2019) 134 (Supplement_1): 5246.

https://doi.org/10.1182/blood-2019-127152

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Mantle cell lymphoma continues to surprise, and inform!

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Under the cover of mantle cell lymphoma

The different flavors and splices of MCL

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Cellular and Molecular Characterization of Breast Cancer Chemotherapy-Related B Cell Lymphomas

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only